Metraipolis › archive › dc_5490d635aa29

Application of antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma: mechanisms, treatment-related adverse events, and management… — Europe PMC PMID:41988515

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41988515
DOI
10.3389/fphar.2026.1771653
License (as archived)
solo-consultazione
Archived
2026-11-03T15:13:38.382Z
SHA-256 of the archived text
a67598b36fe852f0603122143c0ab5fa0a87e66851f60c3265a8aa24f747feb9
Stable URL of this page
https://metraipolis.com/documento/dc_5490d635aa29

How to cite

Application of antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma: mechanisms, treatment-related adverse events, and management… — Europe PMC PMID:41988515 — Europe PMC (en), https://europepmc.org/article/MED/41988515 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5490d635aa29 (Metraipolis archive dc_5490d635aa29, sha256 a67598b36fe852f0603122143c0ab5fa0a87e66851f60c3265a8aa24f747feb9)
BibTeX
@misc{dc5490d635aa29,
  title = {Application of antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma: mechanisms, treatment-related adverse events, and management… — Europe PMC PMID:41988515},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41988515},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5490d635aa29; sha256 a67598b36fe852f0603122143c0ab5fa0a87e66851f60c3265a8aa24f747feb9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41988515. Agents can read the archived copy with the MCP tool read_document.